Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.66 |
| ▸ | HSPA8 | P11142 | 4/20 | 0.59 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | GAPDH | P04406 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144992 | 1.00 | ADK (0.66) | ADKHSPA8HSPA5RXFP1GAPDH | |
| SCHEMBL8494362 | 0.88 | HSPA5 (0.61) | ADKHSPA8HSPA5RXFP1GAPDH | |
| SCHEMBL8494383 | 0.88 | HSPA5 (0.61) | ADKHSPA8HSPA5RXFP1GAPDH | |
| 8-Chloroadenosine SCHEMBL26788558 | 0.87 | HSPA8 (0.78) | ADKHSPA8HSPA5RXFP1GAPDH | |
| 8-Chloroadenosine SCHEMBL19680324 | 0.87 | HSPA8 (0.78) | ADKHSPA8HSPA5RXFP1GAPDH | |
| 8-Chloroadenosine SCHEMBL987728 | 0.87 | HSPA8 (0.78) | ADKHSPA8HSPA5RXFP1GAPDH | |
| 8-Chloroadenosine SCHEMBL31064773 | 0.87 | HSPA8 (0.78) | ADKHSPA8HSPA5RXFP1GAPDH | |
| 8-Chloroadenosine SCHEMBL987731 | 0.87 | HSPA8 (0.78) | ADKHSPA8HSPA5RXFP1GAPDH | |
| SCHEMBL18952787 | 0.86 | ADK (0.65) | ADKHSPA8HSPA5RXFP1GAPDH | |
| SCHEMBL18952790 | 0.86 | ADK (0.65) | ADKHSPA8HSPA5RXFP1GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325698-A1 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250027078-A1 | DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME | CARIBOU BIOSCIENCES, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4438729-A2 | CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS | Caribou Biosciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024178065-A2 | CRIPPLED CORONAVIRUS: 5'-POLYU TARGETED OLIGO PREVENTS DEVELOPMENT OF INFECTIOUS VIRIONS | HOWARD UNIVERSITY (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240263180-A1 | SMALL COMPLEMENTARY NUCLEIC ACIDS, COMPOSITIONS CONTAINING THE SAME, AND METHODS FOR USE AS ANTIVIRALS | HOWARD UNIVERSITY (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4347835-A1 | SMALL COMPLEMENTARY NUCLEIC ACIDS, COMPOSITIONS CONTAINING THE SAME, AND METHODS FOR USE AS ANTIVIRALS | Howard University (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023201270-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-4229198-A2 | DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME | Caribou Biosciences, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022086846-A9 | DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME | CARIBOU BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20030040502-A1 | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | INOTEK PHARMACEUTICALS CORPORATION | 2003-02-27 | — | — | US | disclosed |
| WO-2002076400-A2 | INOSINE COMPOUNDS AND THEIR USE FOR TREATING OR PREVENTING AN INFLAMATION OR A REPERFUSION DISEASE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020052420-A1 | Method and composition for modulating an immune response | INOTEK PHARMACEUTICALS CORPORATION | 2002-05-02 | — | — | US | disclosed |
| US-20010053763-A1 | Method and composition for modulating an immune response | INOTEK PHARMACEUTICALS CORPORATION | 2001-12-20 | — | — | US | disclosed |
| WO-2001052860-A2 | METHOD AND COMPOSITION FOR MODULATING AN IMMUNE RESPONSE | INOTEK CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0499291-A1 | Treatment of malignant tumours with 8-chloroadenosine 3'-5'-cyclic phosphate, 8-aminoadenosine 3',5'-cyclic phosphate and preparation thereof | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1992-08-19 | — | — | EP | disclosed |
| EP-0346400-A4 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | — | 1990-11-28 | — | — | EP | disclosed |
| EP-0346400-A1 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4861873-A | 8-Chloroadenosine 3', 5'-cyclic monophosphate preparations | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-08-29 | — | — | US | disclosed |
| WO-1989005648-A1 | TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5'-CYCLIC PHOSPHATE, 8-AMINOADENOSINE 3',5'-CYCLIC PHOSPHATE AND PREPARATION THEREOF | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053763-A1 | Method and composition for modulating an immune response | SLC11A2, ATP1A2, MSR1 | ADK 411/4885HSPA8 575/4885HSPA5 951/4885 |
| US-20030040502-A1 | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | NOS2, NOS1, ARG2 | ADK 80/4885HSPA8 622/4885HSPA5 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.